直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Federal Circuit PTAB Appeal Statistics for June 2025

July 30, 2025

Authored and Edited by Daniel F. Klodowski; Michelle G. Rice; Jason E. Stach; Elliot C. Cook

In June, a relatively favorable month for appellees, the Federal Circuit issued 20 opinions in appeals from IPR and PGR post-grant proceedings before the Patent Trial and Appeal Board. The court affirmed the PTAB on every issue in 12 cases (60%), including a precedential opinion in Agilent Technologies, Inc. v. Synthego Corp. (No. 23-2186). The court issued three opinions (15%) with mixed outcomes, in which at least one issue was affirmed and at least one issue was not, and dismissed one appeal (5%) on substantive (e.g., non-settlement) grounds in a precedential opinion in Dolby Laboratories Licensing Corp. v. Unified Patents LLC (No. 23-2110). The court rendered four opinions in which every issue was reversed or vacated (20%), including precedential opinions in Eye Therapies, LLC v. Slayback Pharma LLC (No. 23-2173) and Ancora Technologies, Inc. v. Roku, Inc. (No. 23-1674). 

Through June 30, 2025, the Federal Circuit cumulatively decided 1,474 appeals from the PTAB in IPRs, CBMs, and PGRs. While the vast majority of these appeals came from IPR proceedings, the number of PGR appeals has slowly increased over time.

In IPR appeals, the Federal Circuit has cumulatively affirmed the PTAB on every issue in 1,040 cases (74.77%) and reversed or vacated the PTAB on every issue in 170 cases (12.22%). A mixed outcome on appeal occurred in 140 cases (10.06%), and the court dismissed 41 IPR appeals (2.95%) without rendering a decision on the merits. 

In PGR appeals, the Federal Circuit cumulatively affirmed the PTAB on every issue in 19 cases (65.52%), issued a mixed outcome in 3 cases (10.34%), and reversed or vacated every issue in 6 cases (20.69%). 1 PGR appeal (3.45%) has been dismissed on substantive grounds.

Taken together, in decisions for IPR, CBM, and PGR appeals, the Federal Circuit affirmed every issue in 1,100 cases (74.63%), issued a mixed outcome in 147 cases (9.97%), reversed or vacated every issue in 181 cases (12.28%), and dismissed 46 cases (3.12%) on substantive grounds.

Of the 1,474 IPR, CBM, and PGR cumulative appeals that it has considered, the Federal Circuit issued Rule 36 affirmances in 613 cases (41.59%). The court issued written opinions, including affirmances, reversals, dismissals, and mixed decisions, in 861 cases (58.41%). The ratio of Rule 36 affirmances to written decisions has generally trended downward over time, including through June.

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Atlanta, GA

Reston, VA

Washington, DC

Contacts

Daniel F. Klodowski
Partner
Washington, DC
+1 202 408 4216
Email
Michelle_Yongyuan_Rice
Michelle G. Rice
Associate
Washington, DC
+1 202 408 4229
Email
Jason E. Stach
Partner
Atlanta, GA
+1 404 653 6428
Email
Elliot C. Cook
Partner
Reston, VA
+1 571 203 2738
Email

Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Federal Circuit IP Blog

When “and” and “e.g.” Matter: Federal Circuit Revives VLSI vs. Intel Case

May 14, 2026

Federal Circuit IP Blog

Federal Circuit Affirms § 102(b) Invalidity; Source Code Commands Are Not Hearsay

May 14, 2026

IP Updates

Tenth Circuit Sides with Netflix in Tiger King Copyright Challenge 

May 5, 2026

Conference

International Trade Commission Litigation & Enforcement

May 4-5, 2026

Washington, DC

Articles

Unpacking Squires’ Recent Discretionary Denial Guidance Focusing on American Manufacturing

April 24, 2026

Federal Circuit IP Blog

Federal Circuit Affirms District Court’s Invalidation of Patents Because Inventorship Could Not Be Corrected Without Giving All Inventors Notice and an Opportunity to Be Heard

April 22, 2026

Federal Circuit IP Blog

Federal Circuit Reverses Indefiniteness Ruling on Means-Plus-Function Claim

April 15, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP